Aimedbio IPO Preview

615 Views07 Oct 2025 20:25

Aimedbio is getting ready to complete its IPO in KOSDAQ in November 2025. Aimedbio has advanced multiple antibody-drug conjugates (ADC) candidates into preclinical and early clinical stages.

What is covered in the Full Insight:

IPO Overview
Deal Specifics of the Aimedbio IPO
Major Shareholders and Funding
Company Background and Therapeutic Pipeline
Financial Analysis and Projections

Douglas Kim

SUMMARY

(Sign Up to Access)

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Full Insight

(Paid Plans Only, 6-minute read)

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream

A Review of Our IPO Calls in 2025
06 Dec 2025
Aimed Bio IPO Book Building Results Analysis
20 Nov 2025
Aimedbio IPO Valuation Analysis
08 Oct 2025